the ADBL report

Issue #108, June 2019

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

In this issue:

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on March 19, 2019. The Committee reviewed Manufacturer submissions for nineteen (19) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments of the coverage status of twelve (12) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, fifty (50) Drug Products underwent Expedited Review for listing on the *ADBL* effective June 1, 2019.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at https://www.ab.bluecross.ca/dbl/publications.html

Highlights of Products Originally Reviewed via the Common Drug Review (CDR)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* effective April 1, 2019:

- **KEVZARA* 150 mg/1.14 mL & 200 mg/1.14 mL injection syringes** (sarilumab) (SAV) via Special Authorization (SA)
- **KYLEENA 19.5 mg intrauterine insert** (levonorgestrel) (BAI)
- **OCREVUS* 30 mg/mL (10 mL vial) injection** (ocrelizumab) (HLR) via SA
- **REXULTI 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg & 4 mg tablets** (brexpiprazole) (OTS)

The following Drug Product was reviewed by CDR and added to the *ADBL* via Special Authorization effective April 1, 2019:

- **MAVIRET* 40 mg/100 mg tablet** (pibrentasvir/glecaprevir) (ABV)

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (06/2019)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* via Special Authorization effective June 1, 2019:

- **DUODOPA* 20 mg/mL/5 mg/mL (100 mL) intestinal gel** (levodopa/ carbidopa) (ABV)
- **LAPELGA* 6 mg/0.6 mL injection syringe** (pegfilgrastim) (APX)
- **MDK-NITISINONE* 20 mg capsule** (nitisinone) (MEN)
- **MOVAPO* 10 mg/mL pre-filled pen injection** (apomorphine hydrochloride) (PAL)

Highlights of Drug Products Added

The following Drug Product was reviewed by the Expert Committee and added to the *ADBL* via Special Authorization effective June 1, 2019:

- **ERELZI* 25 mg/0.5 mL & 50 mg/mL injection syringes and 50 mg/mL Sensoready auto injector syringe** (etanercept) (SDZ) for the indication of Psoriatic Arthritis (PsA)

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Entry IC Drug Products to the *ADBL* has resulted in the creation of New IC Groupings, effective June 1, 2019:

- **APO-DABIGATRAN* 110 mg & 150 mg capsules** (dabigatran etexilate) (APX) via Step Therapy/Special Authorization
- **AURO-CEFIXIME 20 mg/mL oral suspension** (cefixime) (AUR)

Special Authorization Criteria Changes

The Special Authorization criteria for coverage for the following Drug Products have been revised effective April 1, 2019:

- **EPCLUSA* 400 mg/100 mg tablet** (sofosbuvir/ velpatasvir) (GIL)
- **HARVONI* 400 mg/90 mg tablet** (sofosbuvir/ ledipasvir) (GIL)
- **SOVALDI* 400 mg tablet** (sofosbuvir) (GIL)
- **VOSEVI* 400 mg/100 mg/100mg tablet** (sofosbuvir/ velpatasvir/ voxilaprevir) (GIL)
- **ZEPATIER* 50 mg/100 mg tablet** (elbasvir/ grazoprevir) (MFC)

The Special Authorization criteria for coverage for the following Drug Products have been revised effective June 1, 2019:

- **DAKLINZA* 30 mg & 60 mg tablets** (daclatasvir dihydrochloride) (BMS)

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (06/2019)